First test of new cancer fighter DF6002 shows early promise
NCT ID NCT04423029
Summary
This first-in-human study tested a new drug called DF6002 in 170 patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe dose levels and see if the drug, given alone or with an existing immunotherapy (nivolumab), could shrink tumors. As an early Phase 1 trial, it focused on establishing safety and gathering initial signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health System
Morristown, New Jersey, 07960, United States
-
Augusta University Georgia Cancer Center
Augusta, Georgia, 30912-0003, United States
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Centre Hospitalier Lyon-Sud
Pierre-Bénite, 69495, France
-
Clinica Universidad de Navarra - Madrid
Madrid, 28027, Spain
-
Clinica Universidad de Navarra - Pamplona
Pamplona, 31008, Spain
-
Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
-
Gustave Roussy
Villejuif, 94805, France
-
HealthPartners Cancer Center at Regions Hospital
Saint Paul, Minnesota, 55101, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Hospital Universitari Vall d'Hebrón
Barcelona, 08035, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, 28034, Spain
-
Huntsman Cancer Institute and Hospital
Salt Lake City, Utah, 84112, United States
-
Hôpital Saint-Louis
Paris, 75010, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Local Institution
Boston, Massachusetts, 02215, United States
-
Local Institution - 0022
Heidelberg, 3084, Australia
-
Local Institution - 0023
Box Hill, 3128, Australia
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
SCRI - HealthOne Denver
Denver, Colorado, 80218, United States
-
SCRI - Tennessee Oncology - Saint Thomas West Clinic
Nashville, Tennessee, 37205, United States
-
START Madrid - Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
USOR - Virginia Cancer Specialists - Fairfax Office
Fairfax, Virginia, 22031, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California Irvine
Orange, California, 92868, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.